Physician

Robert Matthew Gelfand, M.D.

According to 2025 Medicare claims, Robert Gelfand, M.D. (NPI: 1407855612) practices hematology/oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is EAST SIDE ONCOLOGY ASSOCIATES PLLC DBA AMERICAN INFUSION CENTER (NPI: 1922287390; TIN: 421742483) and primary practice location at 10128-6828.

Gelfand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,691 traditional Medicare patients, billed 519,061 HCPCS/CPT codes, and received $7,434,297 in Medicare payments. The top billing code was 96401 (Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle). Part D data shows 447 prescription claims across 71 beneficiaries totaling $1,759,828 in drug costs, led by Pomalyst (Pomalidomide). Open Payments data shows 127 records totaling $3,189. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,780,850 to $7,434,297. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $928,805 and ending at $1,759,828. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	427	210,921	$2,780,850
2016	415	163,109	$2,525,759
2017	412	138,657	$2,173,374
2018	609	199,099	$3,147,755
2019	810	238,160	$3,650,560
2020	784	232,617	$3,677,818
2021	812	267,607	$4,338,097
2022	986	308,081	$4,425,506
2023	1,370	430,205	$5,980,021
2024	1,691	519,061	$7,434,297

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	86	566	$928,805
2016	85	542	$1,216,466
2017	67	612	$2,007,523
2018	85	691	$2,191,049
2019	72	541	$958,622
2020	73	521	$1,218,957
2021	70	505	$1,359,958
2022	72	446	$1,005,652
2023	64	392	$1,235,422
2024	71	447	$1,759,828

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	1,014	2,494	$69
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	983	1,543	$51
J0897	Injection, denosumab, 1 mg	832	66,060	$20
36415	Insertion of needle into vein for collection of blood sample	673	1,867	$9
J7050	Infusion, normal saline solution, 250 cc	543	2,912	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	34	945	$715,211
Revlimid	Lenalidomide	22	616	$425,548
Lenalidomide	Lenalidomide	21	588	$314,165
Prolia	Denosumab	20	3,600	$35,544
Xarelto	Rivaroxaban	41	1,380	$25,353

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$3,189	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert Matthew Gelfand, M.D.?

Tedicare shows public-source Medicare data for Robert Matthew Gelfand, M.D. (NPI 1407855612), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert Matthew Gelfand, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert Matthew Gelfand, M.D.?

Robert Matthew Gelfand, M.D. is linked to EAST SIDE ONCOLOGY ASSOCIATES PLLC DBA AMERICAN INFUSION CENTER (billing NPI 1922287390) in the available physician profile data.

Does Robert Matthew Gelfand, M.D. have Open Payments data?

Robert Matthew Gelfand, M.D. has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.